We have previously reported that loss of p53 tumor suppressor protein results in centrosome hyperampli®ca-tion, which leads to aberrant mitosis and chromosome instability. Since p53 is either deleted or mutated in human cancers at a high frequency, we investigated whether human cancers showed centrosome hyperampli®cation. Screening of advanced stage breast ductal carcinomas and squamous cell carcinomas of the head and neck (SCCHN) revealed that centrosome hyperampli®cation is frequent in both tumor types. Moreover, through the analyses of p53 in SCCHN samples by direct sequencing and by loss-of-heterozygosity test, we found that p53 mutations correlated with occurrence of centrosome hyperampli®cation. However, in some cases, we observed centrosome hyperampli®cation in tumors that retained wild-type p53. These tumors contained high levels of Mdm2. Since Mdm2 can inactivate p53 through physical association, we investigated whether Mdm2 overexpression induced centrosome hyperampli®cation. We found that Mdm2 overexpression, like loss of p53, induced centrosome hyperampli®cation and chromosome instability in cultured cells.
Introduction
Chromosome instability, often referred to as karyotypic instability, is frequently observed in a variety of human cancers, and has been shown to correlate with the acquisition of malignant phenotypes (reviewed in Cheng and Loeb, 1993) . Indeed, cancer incidence is increased signi®cantly among people aicted with inherited chromosome instability syndromes such as Bloom's syndrome, ataxia telangiectasia, Fanconi's anemia, Li-Fraumeni syndrome, and Werner syndrome (Cheng and Loeb, 1993) . Moreover, the ploidy changes become more apparent at later stages of tumor progression (Oshimura and Barrett, 1986; Holliday, 1989) . In an experimental system, emergence of aneuploidy has been shown to be strongly correlated with the acquisition of invasive and metastatic phenotypes (Reid et al., 1992) . Chromosome instability, like other types of genomic instability, is believed to play an important role in multi-step carcinogenesis through promoting accumulation of mutations responsible for the malignant phenotypes. The chromosome loss and gain in cancer cells likely results from mitotic aberration. We have recently shown that, in cultured cells, loss of p53 results in centrosome hyperamplification, which in turn leads to a high frequency of aberrant mitosis organized by multiple spindle poles. This results in increased error of chromosome transmission to the daughter cells (Fukasawa et al., 1996 (Fukasawa et al., , 1997 . Centrosomes play vital roles during mitosis as spindle poles, where they are involved in establishing spindle bipolarity, assembling spindle microtubules, determining the plane where the cleavage furrow is introduced, all of which are essential for balanced chromosome segregation. The centrosome must be duplicated only once during each cell cycle to ensure the ®delity of chromosomal segregation in subsequent mitosis. In somatic cells, centrosome duplication begins near the G1/S boundary of the cell cycle as replication of the centriole, the core component of the centrosome in mammalian cells, commences, and is completed in G2-phase (reviewed in Brinkley, 1985; Vandre and Borisy, 1989; Bornens, 1992) .
The p53 tumor suppressor gene is the most frequently mutated gene in human cancer (Hollstein et al., 1991; Levine et al., 1991) . Mutational inactivation and/or deletion of p53 occur in both sporadic and familial cancers, and in various cancer types (Hollstein et al., 1991; Levine et al., 1991) . However, inactivation of p53 function can be achieved by mutations in other cellular proteins that associate with p53, including Mdm2. The mdm2 was initially identi®ed as an ampli®ed gene on a murine doubleminute chromosome in the spontaneously transformed BALB/c 3T3 cells (Cahilly-Snyder et al., 1987) . It was subsequently established as an oncogene, since overexpression of Mdm2 in cultured cells increased the tumorigenic potential of these cells (Fakharzadeh et al., 1991; Finlay, 1993) . Mdm2 binds to p53 at the Nterminal transactivating domain, and inhibits the transactivation function of p53 (Momand et al., 1992; Oliner et al., 1993; Chen et al., 1993; Picksley et al., 1994) . It has been proposed that Mdm2 binding prevents the interaction between essential transcription factors and p53 (reviewed in Momand and Zambetti, 1997; Piette et al., 1997) . More recently, Mdm2 was found to promote the rapid degradation of p53 through the ubiquitin-dependent proteosome pathway (Haupt et al., 1997; Kubbutat et al., 1997) . Thus, the overexpression of Mdm2 results in an eect similar to the mutational inactivation of p53. Mdm2 was also found to be ampli®ed (overexpressed) in a signi®cant proportion of human sarcomas (20 ± 40%) as well as in other types of tumors (reviewed in Momand and Zambetti, 1997) . Importantly, the ampli®cation of Mdm2 occurs preferentially in tumors that do not have p53 mutations (Oliner et al., 1992) . Moreover, Mdm2 gene ampli®cation, like mutational inactivation of p53, was more frequently observed in metastatic or recurrent osteosarcomas than in primary osteosarcomas (Ladanyi et al., 1993) . Thus, the mutational frequencies of p53 in human cancers (over 50% of human sporadic tumors) may underestimate the actual occurrence of p53 inactivation.
In this study we investigated the role of centrosome hyperampli®cation in chromosome instability in human cancer cells. We particularly examined breast ductal carcinomas and squamous cell carcinomas of head and neck (SCCHN), both of which have been shown to harbor p53 mutations at high frequencies (Elledge and Allred, 1994; Ozbun and Butel, 1995; Eyfjord et al., 1995; Raybaud-Diogene et al., 1996) . We found that centrosome hyperampli®cation frequently occurred in both tumor types. Moreover, centrosome hyperampli®cation in SCCHN correlated with either mutation in p53 or Mdm2 overexpression. We further examined whether Mdm2 overexpression, like loss of p53, induced centrosome hyperampli®cation and chromosome instability in cultured cells. We found that the constitutive expression of exogenously introduced Mdm2 resulted in centrosome hyperampli®cation and extensive chromosome instability.
Results

Centrosome hyperampli®cation in human cancers
Because of frequent aneuploidy and p53 mutations/ deletions in human cancers, we tested whether centrosome hyperampli®cation is common in human cancers. We have screened squamous cell carcinomas of the head and neck (SCCHN) and breast ductal carcinomas. The p53 mutations in these tumor types have been shown to be frequent, especially in late stages when extensive aneuploidy becomes apparent (Elledge and Allred, 1994; Ozbun and Butel, 1995; Eyfjord et al., 1995; Raybaud-Diogene et al., 1996) .
The 5-mm-thick paran sections as well as the frozen tissue sections were processed for immunostaining. All the tumors underwent standard pathological evaluation (clinical stage, metastatic node involvement, and degree of dierentiation) by hematoxylin and eosin (H&E) staining. A total of eight breast ductal carcinomas [grade III (Bloom-Richardson grade, Bloom and Richardson, 1957) , poorly dierentiated, lymph node positive], and 12 SCCHN [stage 3 and 4 (UICC), poorly to moderately dierentiated, lymph node positive] were examined. The sections were immunostained for centrosomes using anti-g tubulin polyclonal antibody. The g-tubulin is a major component of centrosomes, and immunostaining for g-tubulin detects centrosomes throughout the cell cycle (Zheng et al., 1991; Stearns et al., 1991; Joshi et al., 1992) . Tissue sections were also stained with DAPI for visualization of nuclei. Both paran and frozen sections gave readily analysable centrosome staining (Figure 1 ). We detected centrosome hyperampli®cation in six out of eight breast ductal carcinomas (representative immunostainings are shown in Figure  1 , panels b and b'), and ten out of 12 SCCHN cases (Table 1 and Centrosome hyperampli®cation in SCCHN correlates with mutation/deletion of p53 and/or Mdm2 overexpression
We further characterized the p53 status of the SCCHN tumors (patient 3 ± 12) by analysis of loss-of-hetrozygosity (LOH) (Gleich et al., 1996) , and by direct sequencing of exons 5 ± 8 (Table 1, Pavelic et al., 1994) . We found two tumors with deletions in one allele and a missense mutation in another allele (Table 1 , patients 4 and 6), three tumors with a missence mutation (LOH not tested, patients 3, 5 and 7), one tumor with wildtype p53 sequence (LOH not tested, patient 10), and four tumors with no apparent mutation in the p53 genes (patients 8, 9, 11 and 12). All of the tumors with mutations in p53 genes showed centrosome hyperampli®cation. However, three tumors that retained wildtype p53 also showed centrosome hyperampli®cation (Table 1) . Recent studies have shown that Mdm2 not only functionally inactivates p53, but also promotes degradation of p53 through physical association (Haupt et al., 1997; Kubbutat et al., 1997) . Thus, we have examined the levels of Mdm2 in all the SCCHN samples by immunohistochemistry. We found that four out of 12 tumors expressed high levels of Mdm2 (Table  1 , representative immunostaining of Mdm2-positive and negative tumor tissues are shown in Figure 2 ), and both of the Mdm2-positive wild-type p53 tumors showed centrosome hyperampli®cation (patients 9 and 10). Consistent with previous ®ndings (Oliner et al., 1992) , we observed Mdm2 overexpression less frequently in the tumors with mutated p53 than those with wild-type p53. One tumor (patient 8) showed centrosome hyperampli®cation despite retention of wild-type p53 and no detectable expression of Mdm2. Mutation of p53 gene in tumors usually results in stabilization and accumulation of the protein, which often reaches levels detectable by immunohistochemistry (for the immunostaining procedure of p53 in archival paran-embedded SCCHN, see Pavelic et al., 1994) . Thus, by immunohistochemical analysis using anti-human p53 monoclonal antibody (Pab 1801), we tested the possibility that p53 in this particular tumor (patient 8) might have undergone mutation(s) outside of exons 5 ± 8. We found that there was no detectable level of p53 in this tumor (data not shown). Despite the limitation of immunohistochemical procedure to dissect the p53 status in tumor tissues, especially when the tumors are immunohistologically negative for p53, these results suggest that mutation(s) in gene(s) other than in p53 or Mdm2 may also induce centrosome hyperampli®cation.
Generation of cells overexpressing Mdm2 proteins
Our observation of Mdm2 overexpression and centrosome hyperampli®cation without alteration in the p53 genes in SCHHN suggests that Mdm2 overexpression may induce centrosome hyperampli®cation in the presence of wild-type p53. To test this, we attempted to generate mouse cell lines which constitutively overexpressed Mdm2 protein. We transfected plasmids encoding either mouse or human Mdm2 together with a plasmid encoding a neomycin resistance gene as a selectable marker into Swiss 3T3 cells (Materials and methods). Swiss 3T3 cells have been shown to retain wild-type p53 (Fukasawa et al., 1991) . Consistent with previous studies (Kubbutat et al., 1997), we observed cytotoxicity associated with overexpression of mouse Mdm2 in Swiss 3T3 cells, and we failed to generate any G-418 resistant colonies that express detectable levels (by Western blot) of exogenously introduced mouse Mdm2 (data not shown). In contrast, G418-resistant colonies which overexpressed human Mdm2 proteins were readily generated. In order to avoid clonal dierences, we pooled the G418-resistant colonies from two independent transfections of human mdm2 plasmids (Mdm2-pool 1 and pool 2). The pooled cells expressed Mdm2 proteins 2 ± 4-fold higher than the endogenous Mdm2 levels (Figure 3) . Moreover, greater than 90% of these pooled cells overexpressed Mdm2 proteins based on immunocytochemical analysis (data not shown).
Since previous ®ndings had indicated that cytotoxicity associated with Mdm2 overexpression is p53-dependent (Kubbutat et al., 1997), we ®rst examined whether the pooled cells overexpressing Mdm2 retain wild-type p53. Mdm2-pool 1 and pool 2, as well as the parental controls Swiss 3T3 cells were examined Paran or frozen sections were used for immunostaining of centrosomes as well as Mdm2. For each sample, normal (nonmalignant) areas adjacent to the tumor lesions were examined as controls. Determination of LOH and sequences of p53 are described in Materials and methods.
a LOH of p53 in the samples have been published (Gleich et al., 1996) .
b Some of the p53 sequences have been published (Pavelic et al., 1994) . by immunoprecipitating p53 from metabolically labeled cell extracts using several dierent anti-p53 antibodies (Figure 4 ): Pab421 that reacts with both wild-type and mutant conformations of p53, Pab246 that reacts only with the wild-type conformation, and Pab240 that reacts only with the mutant conformation (Yewdell et al., 1986; Gannon et al., 1990; Iggo et al., 1990) . p53 proteins in both Mdm2-pool 1 and pool 2 were detected by Pab421 and Pab246, but not by Pab240 (Figure 4) . Although the conformational changes of p53 have been shown to be growth condition-dependent, and some p53 mutants retain immuno-reactivity to Pab246 (Gamble and Milner, 1988) , these studies suggest that both Mdm2-overexpressing lines retain wild-type p53.
Mdm2 overexpression induces centrosome hyperampli®cation and chromosome instability in cultured cells
We immunostained centrosomes in Mdm2-overexpressing cells (Mdm2-pool 1 and 2) as well as in the control Swiss 3T3 cells using anti-g tubulin antibody (for centrosomes) or anti-b tubulin antibodies (for microtubules). We found that *25% of interphase cells overexpressing Mdm2 (Mdm2-pool 1 and 2) contained an abnormal number of centrosomes (more than two centrosomes per cell), while almost all of the parental Swiss interphase cells contained normal number of centrosomes (n=1 or 2) ( Figure 5 , Swiss 3T3 (panels a and a'), Mdm2-pool 1 (panels b and b'), Table 2 ). As expected, mitotic cells that overexpress Mdm2 show a high frequency of aberrant mitotic spindles, while 498% of control Swiss 3T3 cells show normal bipolar spindles ( Figure 5 , Swiss 3T3 (panels c and c'), Mdm2-pool 1 (panels d and d'), Table 2 ).
We next examined the extent of aneuploidy in pooled Mdm2 overexpressing cells. Mdm2-pool 1 as well as control Swiss 3T3 metaphase cells, enriched by treatment with colchicine for 4 h, were harvested and metaphase chromosome spreads were prepared (Materials and methods). The Giemsa-stained chromosomes were directly analysed under a microscope ( Figure 6A ). Swiss 3T3 cells maintained in our laboratory contain stable number of metaphase chromosomes (4N=112). In this experimental procedure, there is unavoidable background noise that interferes with accurate scoring; for example, the spread becomes contaminated by free chromosomes of other mitotic cells which have been ruptured during preparation. In addition, smaller chromosomes (i.e. Swiss 3T3 cells contain four very small chromosomes) often become masked by larger chromosomes in the spread. In order to compensate for this background noise, and to examine statistically signi®cant numbers of metaphase spreads, we have allowed +2 deviation; we scored the chromosome number per cells as 489, 92+2, 97+2, 102+2, 107+2, 112+2, 117+2, 122+2, 217+2, 5130 ( Figure 6B ). Approximately, 90% of the Swiss 3T3 metaphase spreads fell into 112+2. Since the chromosome number of Swiss 3T3 cells is stable, most, if not all, of the minor populations of metaphase spreads scored as 102+2, 107+2, and 117+2 can be considered as background noise. When Mdm2-pool 1 cells were examined, only 20% of the spreads fell into 112+2, and the majority of spreads showed extensive deviation from the original number of chromosomes (4N=112). Figure 6A shows the representative spreads of Swiss 3T3 cells (panel a) and Mdm2-pool 1 (panels b and c). Panel b shows a hypoploid spread, while panel c shows a hyperploid spread. These results demonstrate that, similar to loss of p53 (Harvey et al., 1993b; Purdie et al., 1994; Donehower et al., 1995; Bouer et al., 1995; Fukasawa et al., 1997) , overexpression of Mdm2 results in centrosome hyperampli®cation and extensive chromosome instability. were resolved in 10% SDS ± PAGE, and were subjected to immunoblot analysis using anti-Mdm2 polyclonal antibody (C-18, Santa Cruz). NS indicates non-speci®cally recognized proteins Figure 4 Swiss 3T3 cells overexpressing Mdm 2 retain wild-type p53. Mdm2 overexpressing cells derived from Swiss 3T3 (Mdm2-pool 1 and 2) as well as the parental Swiss 3T3 were examined for p53. Metabolically labeled cell extracts were subjected to immunoprecipitation with Pab421 (recognizing both wild-type and mutant p53), Pab246 (speci®c to wild-type p53) and Pab240 (speci®c to mutant p53) (Yewdell et al., 1986; Gannon et al., 1990; Iggo et al., 1990) . Both Swiss 3T3 cells and Mdm2 overexpressing cells (Mdm2-pool 1 and 2) express p53 recognized only by Pab246, but not by Pab240. NS indicates non-speci®cally precipitated proteins
Discussion
The loss of mutation of p53 leads to certain types of genomic instability, including gene ampli®cations and ploidy changes (Yin et al., 1992; Livingstone et al., 1992; Harvey et al., 1993a,b; Purdie et al., 1994; Donehower et al., 1995; Bouer et al., 1995) . For instance, gene ampli®cation frequencies increase over several orders of magnitude when p53 is deleted or n indicates the number of centrosomes. n ranges from 3 ± 7 in n53. For interphase cells, 4500 cells were examined. For mitotic cells, 4200 cells were examined mutated (Yin et al., 1992; Livingstone et al., 1992) . Moreover, cytogenetic analysis of cultured ®broblasts, as well as tissues derived from p53 7/7 mice have revealed a high degree of aneuploidy (Harvey et al., 1993b; Purdie et al., 1994; Donehower et al., 1995; Bouer et al., 1995; Fukasawa et al., 1997) and spontaneous gene ampli®cation of certain genes, including c-myc and DHFR (dihydrofolate reductase gene) (Fukasawa et al., 1997) . Numerous studies of various human tumors have also shown a strong correlation between mutated or deleted p53 and emergence of aneuploidy (Carder et al., 1993; Blount et al., 1994 ; also reviewed in Smith and Fornace, 1995) . Chromosome instability can contribute to tumor progression by the following possible mechanisms: (1) Loss of chromosomes that harbor genes encoding negative regulators of cell cycle progression, proteins involved in apoptosis or senescence, or suppressors of other cancer-associated phenotypes (i.e., uncontrolled cell growth, metastasis, invasion), (2) gain of extra chromosomes that harbor genes encoding positive regulators of cell cycle progression (oncogenes), or anti-apoptosis as well as antisenescence proteins.
In most cases, chromosome instability re¯ects a high frequency of abnormal mitosis and resulting unequal distribution of chromosomes to daughter cells. Thus, any mutation that disturbs the normal mitotic process has the potential to destabilize chromosomes. Examination of p53 7/7 mouse embro- nic ®broblasts as well as p53 7/7 mice revealed that loss of p53 leads to centrosome hyperampli®cation, which in turn increases the incidence of aberrant mitosis and chromosome instability (Fukasawa et al., 1996 (Fukasawa et al., , 1997 . Here, the examination of centrosomes in two dierent types of tumors, breast ductal carcinomas and SCCHN, reveals that centrosome hyperampli®cation is common in these cancers, and thus, is likely to be one of the major mechanisms underlying chromosome instability in these tumors. Indeed, DNA staining of the tumor tissues frequently identi®ed cells undergoing abnormal mitosis organized by multispindle poles (data not shown). Moreover, the molecular analyses of SCCHN samples showed a correlation between centrosome hyperampli®cation and mutation/deletion of p53 and Mdm2 overexpression. All of the tumors with p53 either deleted or mutated, or both show centrosome hyperampli®cation. Consistent with the previous studies showing that Mdm2 overexpression is common in tumors that retain wild-type p53 (Oliner et al., 1992) , Mdm2 overexpression was detected in two out of ®ve SCCHN tumors that retained wild-type p53. We found that these tumors also showed centrosome hyperampli®cation. With one exception, all tumor samples with wild-type p53 and no Mdm2 overexpression showed no centrosome abnormality. These results suggest that Mdm2 overexpression, like loss or mutation of p53, induces centrosome hyperamplification. To test this possibility, we examined cells overexpressing stably transfected Mdm2 proteins. We found that these cells, despite retaining wild-type p53, showed extensive centrosome hyperampli®cation and chromosome instability, strongly supporting the correlation between Mdm2 overexpression and centrosome hyperampli®cation observed in human cancers. Some previous studies have failed to detect a clear correlation between the p53 mutation and chromosome instability (Lengauer et al., 1997) . Although these contrasting results may be due to dierences in tumor types examined or dierences in experimental systems (tumor cell lines vs tumor tissues), they may also be due to inactivation of p53 by mechanisms other than mutation of the p53 gene itself, such as Mdm2 overexpression, facilitating chromosome instability by inducing abnormal ampli®cation of centrosomes. The relationship between p53 mutation and/or Mdm2 overexpression and centrosome hyperampli®cation (and resulting chromosome instability) in human cancers can be established more ®rmly by analyses of more samples, tumors at dierent stages, as well as other tumor types. With such analyses, centrosome hyperampli®cation might be potentially useful as a prognostic indicator of human cancer progression.
At present, we have not eliminated the possibility that mutational activation or inactivation of other proteins, which play roles in the control of the centrosome duplication cycle, may lead to centrosome hyperampli®cation in cancers. Indeed, we observed one SCCHN sample showing centrosome hyperampli®cation in the absence of p53 alteration or Mdm2 overexpression. Further understandings of the molecular mechanisms that control the centrosome duplication cycle in somatic cells will be necessary to identify such proteins.
Materials and methods
Cells and transfection
Swiss 3T3 cells were maintained in complete medium (DMEM supplemented with 10% fetal bovine serum (FBS) with penicillin (100 U/ml) and streptomycin (100 mg/ml)) and grown in an atmosphere containing 10% CO 2 . The transfections were performed by the calcium phosphate procedure described previously (Graham and van der Eb, 1973) . Cells were subconuently plated 24 h before transfection, and were fed with fresh medium 4 h before transfection. Cells were transfected with plasmids encoding either a mouse mdm2 gene (pCOC-X2) or a human mdm2 gene (mdm2-pCMV5), together with a plasmid encoding a neomycin-resistance gene (pKOneo) at 30 : 1 molar ratio. After incubation for 12 h at 378C, the cells were washed twice with medium and fed with fresh complete medium. Twenty four hours later, the cells were replated at a density of 3610 5 cells per 100-mm dish. Medium was changed to complete medium supplemented with G418 (400 mg/ml). The colonies that formed 2 weeks after transfection were pooled, and maintained for further experimentation.
Indirect immuno¯uorescence
The paran and frozen tumor blocks were retrieved from the tissue archives (Department of Pathology, University of Cincinnati College of Medicine). The 5-mm-thick sections cut from the paran block were deparanized and processed for immunostaining as described (Harlow and Lane, 1988) . The snap frozen specimens were prepared as previously described (Gapany et al., 1993) , cut at 5 mm thickness, and ®xed in ice cold methanol. Cultured cells grown on slides were washed twice with phosphate buered saline (PBS) and ®xed with 10% formalin for 20 min at room temperature. The cells were then washed with PBS and permeabilized with 1% Nonidet P-40 (NP-40) in PBS for 5 min at room temperature. Tissues and cells were ®rst incubated with blocking solution (10% normal goat serum in PBS) for 1 h and then probed with anti-gtubulin polyclonal antibody (Fukasawa et al., 1997) or with anti-b-tubulin monoclonal antibodies (TUB2-1 (Sigma) and DM1B (ICN Biomedical)) for 1 h. For Mdm2 staining, anti-Mdm2 polyclonal antibody (clone C-18, Santa Cruz) was used. The antibody-antigen complexes were detected with rhodamine-conjugated goat anti-mouse IgG antibody for b-tubulin and FITCconjugated goat anti-rabbit IgG antibody for g-tubulin (as well as Mdm2) (Boerhinger Mannheim) by incubation for 1 h at room temperature. The samples were washed three times with TBS after each incubation, and then stained with 4',6-diamidino-2-phenylindole (DAPI) DNA dye.
Loss of heterozygosity (LOH) test and sequence analysis of p53
In order to detect LOH of p53 on chromosome 17, the probes p144-D6 and pYNZ22 were used to detect variable number of tandem repeat markers as described previously (Kondoleon et al., 1987; Vissing et al., 1987; Nakamura et al., 1987; Gleich et al., 1996) . The LOH of p53 of the tumor samples described in this communication has been published in Gleich et al. (1996) . Ampli®cation of p53 DNA sequences (exon 5 ± 8) using PCR was performed as previously described (Pavelic et al., 1994) . The gel-puri®ed, ampli®ed DNA was sequenced as described (Pavelic et al., 1994) . The p53 sequences of some of the tumor samples used in this study have been published (Pavelic et al., 1994) .
Immunoblot analysis
Cells were washed twice in PBS and lysed in SDS-NP-40 lysis buer (1% SDS, 1% NP-40, 50 mM Tris (pH 8.0), 150 mM NaCl, 4 mM Pefabloc SC (Boerhinger Mannheim), 2 mg/ml leupeptin, 2 mg/ml aprotinin). The lysates were brie¯y sonicated to break DNA, boiled for 5 min and then cleared by a 10 min centrifugation at 20 000 g at 48C. The supernatant was further denatured at 958C for 5 min in sample buer (2% SDS, 10% glycerol, 60 mM Tris (pH 6.8), 5% b-mercaptoethanol, 0.01% bromophenol blue). Samples were resolved by SDS ± PAGE, and fractionated proteins were transferred to Immobilon (Milipore) sheets. The blots were incubated in blocking buer [5% (wt/vol) nonfat dry milk in Tris-buered saline+Tween 20 (TBS-T)] for 1 h at room temperature and then anti-Mdm2 polyclonal antibody (C-18, Santa Cruz) for 4 h at room temperature. The blots were then rinsed in TBS-T and incubated with horseradish peroxidase-conjugated goat anti-rabbit IgG for 1 h at room temperature. The blots were rinsed in TBS-T, and the antibody-antigen complex was visualized by ECL chemiluminescence (Amersham) according to the manufacturer's instructions.
Immunoprecipitation
Cells growing at a subcon¯uent density were washed three times with methionine (met) and cysteine (cys)-free DMEM and incubated in met, cys-free DMEM supplemented with 75 mCi/ml 35 S-labelled met and cys (trans 35 S-label, ICN Biomedical) with 5% dialyzed FBS. After metabolical labelling for 3 h, cells were washed with PBS three times, and then lysed in NP-40 lysis buer [1% NP-40, 150 mM NaCl, 50 mM Tris (pH 8.0), 4 mM Pefabloc SC, 2 mg/ml leupeptin, 2 mg/ml aprotinin]. The lysates were cleared by centrifugation for 15 min at 20 000 g at 48C. The lysates containing 200 mg of total proteins were immunoprecipitated with the following anti-p53 monoclonal antibodies: Pab421 (Oncogene Science), Pab246 and Pab240 (Santa Cruz). The antibody-antigen complexes were collected with protein G-agarose, and washed four times with NP-40 lysis buer. The immunocomplexes were then denatured in sample buer at 958C for 5 min and resolved by 10% SDS ± PAGE.
Metaphase spread and chromosome counting
The metaphase spread was prepared as described previously (Fukasawa et al., 1997) . Brie¯y, proliferating cells were incubated in the presence of colcemid (0.5 mg/ml) for 4 h to enrich mitotic cells. The medium which contained some of the rounded-up mitotic cells was saved. The remaining cells were trypsinized, and together with the saved medium, cells were pelleted by centrifugation. The cell pellet was gently resuspended in hypotonic solution (0.075 M KCl), and allowed to stand for 20 min at room temperature. After removal of hypotonic solution, a methanol-acetic acid ®xative was added, and cells were allowed to stand for 5 min. After discarding the old ®xative, fresh ®xative was added. This procedure was repeated an additional two times. After the last change of ®xative, a few drops were placed on microscope slides, and dried at 378C. The dried samples were subjected to Giemsa staining, and analysed under a microscope.
